The effect of chemotherapy regimens in male germ cell tumors on the development of primary hypogonadism

This study investigated the risk of developing primary hypogonadism in male germ cell tumor (GCT) survivors, focusing on adherence to guideline-recommended therapy. Conducted at a tertiary cancer center, the study involved 44 participants out of 402 contacted, with 32 undergoing blood analysis. Results showed that 28% had latent hypogonadism and 25% had manifest hypogonadism. Additionally, 50% reported erectile dysfunction, and 62.8% experienced symptomatic effects. The findings highlight the prevalence of hypogonadism in GCT survivors and emphasize the importance of evaluating endocrine function in this population. The study also addressed challenges in research participation and suggested ways to overcome these barriers.